Acelyrin, Inc. (NASDAQ:SLRN) Holdings Lifted by Wells Fargo & Company MN

Wells Fargo & Company MN raised its holdings in Acelyrin, Inc. (NASDAQ:SLRN) by 21.9% in the fourth quarter, Holdings Channel.com reports. The fund owned 52,014 shares of the company’s stock after acquiring an additional 9,332 shares during the period. Wells Fargo & Company MN’s holdings in Acelyrin were worth $163,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the business. RPO LLC acquired a new stake in Acelyrin during the fourth quarter valued at approximately $46,000. Virtu Financial LLC acquired a new position in shares of Acelyrin in the 3rd quarter worth $50,000. Intech Investment Management LLC raised its position in shares of Acelyrin by 71.0% during the fourth quarter. Intech Investment Management LLC now owns 26,587 shares of the company’s stock worth $83,000 after purchasing an additional 11,040 shares during the period. American Century Companies Inc. lifted its holdings in shares of Acelyrin by 146.0% during the fourth quarter. American Century Companies Inc. now owns 78,868 shares of the company’s stock valued at $248,000 after purchasing an additional 46,802 shares during the last quarter. Finally, ExodusPoint Capital Management LP acquired a new position in shares of Acelyrin in the 4th quarter valued at $423,000. Institutional investors own 87.31% of the company’s stock.

Acelyrin Trading Down 4.1 %

NASDAQ SLRN opened at $2.36 on Friday. Acelyrin, Inc. has a 1 year low of $1.85 and a 1 year high of $7.25. The stock’s 50-day moving average price is $2.46 and its two-hundred day moving average price is $3.13. The company has a market cap of $238.14 million, a PE ratio of -0.96 and a beta of 1.07.

Acelyrin (NASDAQ:SLRN) last issued its quarterly earnings results on Wednesday, March 19th. The company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.07. Research analysts forecast that Acelyrin, Inc. will post -2.53 EPS for the current fiscal year.

Insider Activity

In related news, CEO Mina Kim sold 17,986 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $2.74, for a total transaction of $49,281.64. Following the transaction, the chief executive officer now directly owns 671,753 shares of the company’s stock, valued at approximately $1,840,603.22. The trade was a 2.61 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 13.60% of the stock is currently owned by corporate insiders.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.